Why selling when there are a lots of good news to be announce soon ?

It's normal after Dividend EX date.
Next week or Next month it will go back to 4.90 or 5.00.

4.92 closing before 5 pm eat all.

So much effort have been done on TauRX and Genting will try their best to push for approval.
Just wait for good news. Hold and don't sell.

Holding power will win.
TauRX shouldn't be a problem getting approved.

Good support at RM5.
Next week all the best.

Still washing.
Washing until water is very clear then start moving up.

Just hold or buy more. No need to do anything. Just wait for TauRX. Heng Ah, Ong Ah, Huat Ah.

GenP and GenM dividend will contribute to GenB CASH on hand.

A very good close. Washing all weak holders. Continue washing for another few days. Next target price will be 5.30, then 5.50 then 6.00. keep washing and continue go higher.

Washing before go higher.

https://theedgemalaysia.com/node/704256

Genting’s Resorts World Bet achieved US$500,000 wagering revenue in February — report

KUALA LUMPUR (March 12): Resorts World Bet, an offshoot of the Genting group, achieved US$500,000 (RM2.34 million) in wagering revenue, as online sports wagering revenue in the New York state rose 21% in February, with a hold percentage of 7.4%, slightly lower than industry standards.

In a report on Sunday, North America's gambling industry news source CDC Gaming said handle (money bets) was also up 21%, at almost US$1.8 billion wagered.

The report said revenue before taxes was US$131.4 million.
One operator, Fanatics Sportsbet, participated in the market for only one day, having launched on Feb 29.

Although substantially increased handle was seen at DraftKings (up 24%), FanDuel (22%), and BetMGM (20%), only the first two increased revenue.

BetMGM lost ground in revenue, while Caesars Sportsbook ceded both handle and revenue alike.

DraftKings grossed US$53.4 million on US$608 million in handle, a 59% surge.
FanDuel led in both handle (US$720 million) and revenue (US$63.4 million), the latter a 19% increase.

BetMGM booked US$130 million in wagers, but realised revenue of only US$600,000.

Washing before go higher.

https://theedgemalaysia.com/node/704204

According to Bloomberg, of the 16 analysts covering the stock, 14 have “buy” calls on Genting while two recommended “hold”.

Worth noting is that Genting’s share price rally comes after Maybank Investment Bank Research said its target price for the group could be revised upward to RM9.40 under the blue sky scenario where TauRx’s hydromethylthionine mesylate (HMTM) drug is approved and the pharmaceutical company is valued at US$15 billion (RM70.23 billion), up from US$1 billion currently.

HLIB has upgraded its target price for Genting to RM7.12, from RM6.96 previously, due to the group being undervalued as it does not sufficiently capture the potential recovery of both its subsidiaries, Genting Singapore Ltd and Genting Malaysia Bhd.

Genting Berhad management is very confident they will be getting TauRX approval. That is reason insiders pushing the share price up before announcement.

Waiting for TauRX announcement. Once approved. Maybank TP 9.40.

AngTayKor....I support you. Buy more and laughing all the way to the Bank.

GenM got nothing to do with TauRX. Only GenB.

I think Genting Berhad insider already know the good news. Pending official announcement.

Continue holding. Turbo Engine just started.

https://theedgemalaysia.com/node/703916

Genting’s target price could be raised to as high as RM9.40 under a blue sky scenario, where HMTM is approved and TauRx is valued at US$15 billion (RM70.3 billion) without discount, the research house added.

TP RM9.40

We are pleased to confirm receipt of investigative new drug (IND) approval from the National Medical Products Administration (NMPA) in China for study TRx-237-801. dMed-Clinipace, a global CRO based in Shanghai, has been selected as the research partner for this study.
We estimate that 60% of the global burden of AD is in Asian countries compared with only 12% in Europe and US combined.

Submitted for approval. Once approved no problem breaking RM7.

Eli Lilly got any thing to do with TauRX?

Cannot do anything. Just wait until the durian drop.

When can get official approval ? soon ?

Afternoon closing price very important.

https://theedgemalaysia.com/node/703916

KUALA LUMPUR (March 8): TauRx Pharmaceuticals Ltd, the 20%-owned associate of Genting Bhd, said new data show that its trial drug to combat Alzheimer's disease has “sustained benefits” across the disease spectrum from early to moderate dementia.

The new 24-month data from the third phase of the so-called LUCIDITY trial of hydromethylthionine mesylate (HMTM) showed “significantly” reduced disease progression in participants, TauRx said in a statement following a presentation at a conference in Portugal.

Genting’s target price could be raised to as high as RM9.40 under a blue sky scenario, where HMTM is approved and TauRx is valued at US$15 billion (RM70.3 billion) without discount, Maybank said.

https://www.nst.com.my/amp/business/2022/06/804468/genting-set-early-monetisation-associate-firm-taurx

RHB Research said TauRx could contribute RM1.3 billion-RM4.3 billion to Genting's financial year 2024 (FY24)-FY26 earnings, assuming a 10 per cent net margin.

KUALA LUMPUR: Merger and acquisition (M&A) of Genting Bhd's 20.3 per cent-owned research and development (R&D) associate TauRx Pharmaceuticals Ltd could allow for faster monetisation versus initial public offering (IPO), RHB Research said.
The firm said while Genting did not comment on its strategy with regards to its TauRx stake, any option of value realisation or monetisation was definitely a positive after having invested in the firm since November 2012.
"For TauRx to IPO, it would need to first commercialise its lead investigative oral drug, HMTM, in 2023 and undertake listing in 2024 or later.

"Conversely, we think M&A or in-licensing agreements may allow for earlier monetisation of Genting's stake, given that large pharmaceutical firms may have M&A interest in TauRx in order to possess the world's only effective Alzheimer's treatment.

"As a plus, M&A could allow TauRx to leverage on such firms' resources to expedite HMTM speed to market," it said in a note today. RHB Research said the HMTM drug would need to undergo 12 months of open-label trials – it could seek regulatory approvals for this Alzheimer's drug before the trial's conclusion.

RHB Research said TauRx could contribute RM1.3 billion-RM4.3 billion to Genting's financial year 2024 (FY24)-FY26 earnings, assuming a 10 per cent net margin.
It could also fetch an upside of RM3.47-RM13.88 a share share based on 10x price to earnings ratio (P/E) on our base and bull cases for FY24 earnings," it said.

RHB said this could translates to hypothetical target price of RM9.84-RM20.25 for Genting.

Genting always got disappointment and surprises.

Don't give up 愛拼才會贏.

Genting Berhad
TauRX tomorrow presentation day.
愛拼才會贏

Interesting.
Afternoon not sure got magic show ?

https://www.businesstoday.com.my/2024/03/05/all-eyes-on-gentings-taurx-alzheimer-phase-3-trial/

On 7 Mar 2024, Genting Berhad’s 20%-owned TauRx will present full results from its Phase 3 LUCIDITY trial of HMTM that is designed to combat Alzheimer’s disease. It has initiated regulatory engagement in the United Kingdom and the United States for product approval.

Under a ‘blue sky’ scenario where HMTM is approved and TauRx is valued at USD15b with no discount ascribed to it, Maybank IB says GENT TP could be raised to MYR9.40. As for now the house estimates MYR5.73 TP unchanged but encourages investors to BUY now to position ahead.

AngTayKor
Your update is very important and useful. Please continue.

I would have sold all my Genting long time ago.
It's because of TauRX, I am still holding until now.
Hopeless hope. Very disappointed.

Maybank IB advises investors to look at Genting given its involvement in life sciences

NST Tue, Mar 05, 2024 12:12pm - 51 minutes .....latest news just came in.

Q3 result not yet out ?

AngTayKor...... thanks

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.

Tomorrow.

1) sell that land in US fast.
2) IPO Las Vegas hotels and Casino.
3) TauRX launching.
Genting management please work harder and faster. Wake up.

Too many containers only a few covers. Hoping for the best.

Kindly be advised of the following :

1) The above Company's securities will be traded and quoted "Ex - Dividend” as from: 20 Mar 2024
2) The last date of lodgment : 21 Mar 2024
3) Date Payable : 19 Apr 2024

Why selling like the end of the world.
The company is still making good profit and can afford to pay dividend.

https://www.thestar.com.my/business/business-news/2024/03/01/genting039s-outlook-boosted-by-multiple-factors

????????

If you are not happy with the results, just sell. To me the results is reasonable. Will wait for TauRX progress.

GenM dividend 9 cents

Check bursa announcement

GenM results out already. Quite good 👍

Really pity those got force selling. Never learn. No money don't buy and don't play contra.